)
Lupin Limited on August 27, 2015 announced that it has received final approval for its omeprazole delayed-release capsules 40 mg, a generic version of AstraZeneca’s Prilosec capsules, from the US Food and Drugs Administration (US FDA).
Lupin's omeprazole delayed-release capsule is indicated for the short-term treatment of duodenal ulcer, gastric ulcer, treatment of gastro esophageal reflux disease (GERD), maintenance of healing of erosive esophagitis and pathological hypersecretory conditions.
According to IMS MAT June 2015 report, Prilosec had annual US sales of $ 185 million.
